


DEPOSITARY RECEIPTS



NEW DR ANNOUNCEMENT

Oasmia Pharmaceutical AB

Oasmia Pharmaceutical researches, develops, and manufactures drugs for human and veterinary oncology in Sweden. The Company focuses on manufacturing formulations based on cytostatics. The Company's drug candidates for human health include Paclical, a Phase III clinical trial product for the treatment of ovarian cancer; Doxophos, a formulation of doxorubicin for the treatment of cancer; and Docecal, a patented formulation of docetaxel. The Company's product candidates for animal health comprise Paccal Vet, a formulation of paclitaxel for the treatment of mastocytoma, mammary carcinoma, and squamous-cell carcinoma in dogs; and Doxophos Vet, a Phase I clinical trial product for the treatment of lymphoma in dogs.

DR Name: Oasmia Pharmaceutical

Effective Date: October 28, 2015

Country of Incorporation: Sweden

Exchange: NASDAQ Stock Market

Type of ADR Program: Sponsored - Level III

Ticker Symbol: OASM

CUSIP Number: 67421W109

Ratio (DR:ORD): 1:3
Underlying Share Description: Ordinary

Industry Classification: Pharma. & Biotech.

Custodian(s): SEB Merchant Banking

Svenska Handelsbanken

To learn more about ADRs and issuer programs, please call our marketing desks:

New York Hong Kong London

Ravi Davis Herston Powers Jacek Jankowski
Adrdesk@bnymellon.com Vice President DR Broker Liaison

Tel: 212 815 2267 herston.powers@bnymellon.com jacek.jankowski@bnymellon.com

Tel: 65 6432 0281 Tel: 442071637427

Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon and are subject to investment risks including possible loss of principal amount invested.

This announcement and the information contain herein is provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this information. We provide no advice or recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. An offering is made by means of a prospectus only. BNY Mellon is regulated by the FSA.